Associated Papers
Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma.
Nokchan N et al.
Journal of Personalized Medicine, 2024
39338204 (PubMed )
Supplement: jpm-14-00950-s001.zip › Supplementary_Table_S2.xlsx › Supplementary_Table_S2.
Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies.
Flümann R et al.
Blood Cancer Discovery, 2023
36346827 (PubMed )
Supplement: bcd-22-0007_table_s6_suppst6.xlsx › E_Mut_Pat.__4
de novo variant calling identifies cancer mutation signatures in the 1000 Genomes Project.
Ng JK et al.
Human Mutation, 2022
36054329 (PubMed )
Supplement: HUMU-43-1979-s002.xlsx › S14_IGLL5_DNVs
Whole-exome sequencing analysis identifies distinct mutational profile and novel prognostic biomarkers in primary gastrointestinal diffuse large B-cell lymphoma.
Li SS et al.
Experimental Hematology & Oncology, 2022
36243813 (PubMed )
Supplement: 40164_2022_325_MOESM5_ESM.xlsx › Sheet1
Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma.
Fangazio M et al.
Proceedings of the National Academy of Sciences of the United States of America, 2021
34050029 (PubMed )
Supplement: pnas.2104504118.sd02.xlsx › Table_S2
Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence.
Magnes T et al.
Esmo Open, 2021
33399078 (PubMed )
Supplement: mmc1.pdf
Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
Evrard SM et al.
Haematologica, 2019
Select a paper to view details